# Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Source: https://onco.cc/trials/nct05263583/  
OnCo record `nct05263583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sepantronium Bromide in non-Hodgkin lymphoma, burkitt lymphoma and diffuse large B-cell lymphoma, run by Cothera Bioscience, Inc, active and no longer recruiting.

## Summary

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma is a phase 2 interventional study registered as NCT05263583 by Cothera Bioscience, Inc, with 14 participants enrolled, started 2022-12-09 and due to reach its primary completion in 2025-03-01. Interventions recorded: Sepantronium Bromide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05263583
- Phase: 2
- Setting: A Phase 2, Multicenter, Open Label Dose-ranging Study of Sepantronium Bromide in Patients With Relapsed/Refractory c-Myc Rearranged High-grade B-cell Lymphoma (HGBCL)
- Sponsor: Cothera Bioscience, Inc
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT05263583: https://clinicaltrials.gov/study/NCT05263583

## Connected records

- cancers: [Burkitt lymphoma](https://onco.cc/cancers/burkitt-lymphoma/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05263583.json